Jin Rong Jie·2025-08-18 09:28Core Viewpoint - China Biopharmaceutical (01177.HK) reported a revenue of approximately 17.575 billion RMB for the six months ending June 30, 2025, reflecting a year-on-year increase of 10.7% [1] - The net profit attributable to shareholders was 3.389 billion RMB, up 12.3% year-on-year, with basic earnings per share at 0.1882 RMB [1] Financial Performance - Revenue for the first half of 2025 reached 17.575 billion RMB, marking a 10.7% increase compared to the previous year [1] - Net profit attributable to shareholders was 3.389 billion RMB, which is a 12.3% increase year-on-year [1] - Basic earnings per share were reported at 0.1882 RMB [1] - The company proposed an interim dividend of 0.05 HKD per share [1] Product Development - During the reporting period, the company received NMPA approval for two innovative products: Putan Ning (Meloxicam Injection (II)) and Anqi Xin (Recombinant Human Coagulation Factor VIIa N01 Injection) [1] - Revenue from innovative products reached 7.8 billion RMB in the first half of 2025, representing a year-on-year growth of 27.2% [1] - Additionally, five generic drugs received NMPA approval, with overall revenue from generics maintaining positive growth in the first half of 2025 [1]